AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19173181 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y‐ibritumomab tiuxetan (1200 MBq max dose)
Number of subjects: 62
Study 16895488 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic warming using a disposable forced warm-air blanket
Number of subjects: 0
Study 16895488 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductive carbon polymer mattress and overblanket
Number of subjects: 0
Study 16895488 — intervention group
Group type: EXPERIMENTAL
Intervention: Local warming with non-contact radiant heat
Number of subjects: 0
Study 16895488 — intervention group
Group type: COMPARATOR
Intervention: Standard care without local warming
Number of subjects: 0
Study 17163896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' knowledge of EBP
Number of subjects: 160
Study 17163896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' beliefs about the benefits of EBP
Number of subjects: 160
Study 17163896 — intervention group
Group type: EXPERIMENTAL
Intervention: Having an EBP mentor
Number of subjects: 160
Study 17163896 — intervention group
Group type: EXPERIMENTAL
Intervention: Using the Cochrane Database of Systematic Reviews and the National Guideline Clearinghouse
Number of subjects: 160
Study 11476298 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal row carpectomy
Number of subjects: 0
Study 11476298 — intervention group
Group type: COMPARATOR
Intervention: Arthrodesis of the radiocarpal joint
Number of subjects: 0
Study 11476298 — intervention group
Group type: COMPARATOR
Intervention: Excision of the scaphoid combined with midcarpal arthrodesis
Number of subjects: 0
Study 9372504 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dose (TD) gadolinium (0.3 mmol/kg)
Number of subjects: 15
Study 9372504 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (s.d.) gadolinium (0.1 mmol/kg)
Number of subjects: 15
Study 9372504 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed scanning (DS) after TD
Number of subjects: 15
Study 7941662 — intervention group
Group type: EXPERIMENTAL
Intervention: QT-interval pacing
Number of subjects: 0
Study 7941662 — intervention group
Group type: EXPERIMENTAL
Intervention: Minute ventilation (MV) pacing
Number of subjects: 0
Study 2975228 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach
Number of subjects: 30
Study 2975228 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 30
Study 29559344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab treatment
Number of subjects: 114
Study 27475688 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketorolac 10 mg plus intramuscular placebo (1 mL saline solution)
Number of subjects: 30
Study 27475688 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular tramadol 50 mg diluted in 1 mL saline solution plus oral placebo (similar tablet to oral ketorolac)
Number of subjects: 30
Study 24047817 — intervention group
Group type: COMPARATOR
Intervention: Tetravalent vaccine and placebo
Number of subjects: 601
Study 24047817 — intervention group
Group type: COMPARATOR
Intervention: A/H5N1 vaccine and placebo
Number of subjects: 601
Study 24047817 — intervention group
Group type: COMPARATOR
Intervention: A/H5N1 and seasonal vaccines
Number of subjects: 601
Study 23368891 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-guided biliary cannulation (WGC)
Number of subjects: 322
Study 23368891 — intervention group
Group type: COMPARATOR
Intervention: Conventional cannulation (CC)
Number of subjects: 322
Study 23368891 — intervention group
Group type: EXPERIMENTAL
Intervention: Accidental guidewire insertions and unintended injections of contrast into the main pancreatic duct
Number of subjects: 322
Study 20651217 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (12 weeks, 5 days/week, 1 hour/day at 65% Vo(2peak))
Number of subjects: 10
Study 20651217 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (12 weeks)
Number of subjects: 10
Study 18793563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg)
Number of subjects: 40
Study 18793563 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional oral agents alone)
Number of subjects: 40
Study 16802853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (320 microg ex‐actuator; equivalent to 400 microg ex‐valve) via HFA‐MDI with AeroChamber Plus spacer
Number of subjects: 30
Study 16802853 — intervention group
Group type: COMPARATOR
Intervention: Ciclesonide (320 microg ex‐actuator; equivalent to 400 microg ex‐valve) via HFA‐MDI without AeroChamber Plus spacer
Number of subjects: 30
Study 12890927 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype-environment interaction testing method
Number of subjects: 0
Study 10615840 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing at least one stressful life event during the periconceptional period
Number of subjects: 0
Study 10615840 — intervention group
Group type: COMPARATOR
Intervention: Control group (women not experiencing stressful life events)
Number of subjects: 0
Study 9239580 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic Group (T reduced to 32.0 degrees C)
Number of subjects: 19
Study 9239580 — intervention group
Group type: COMPARATOR
Intervention: Control Group (T maintained at 35.5 degrees C)
Number of subjects: 19
Study 9239580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 1586733 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic heparin 100 U/kg/d by continuous infusion from day -8 until day +30 post-BMT
Number of subjects: 161
Study 1586733 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 161
Study 1586733 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic heparin after allogeneic BMT
Number of subjects: 161
Study 1586733 — intervention group
Group type: COMPARATOR
Intervention: Control group after allogeneic BMT
Number of subjects: 161
Study 1586733 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 161
Study 3032827 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre tablets
Number of subjects: 60
Study 3032827 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 60
Study 29447076 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork collagen peptide (CP) 2.5 g/day
Number of subjects: 70
Study 29447076 — intervention group
Group type: COMPARATOR
Intervention: Placebo 2.5 g/day
Number of subjects: 70
Study 27007213 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab with standard care
Number of subjects: 0
Study 27007213 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 24422726 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HNE-conjugates
Number of subjects: 349
Study 24422726 — intervention group
Group type: EXPERIMENTAL
Intervention: AOPP
Number of subjects: 349
Study 24422726 — intervention group
Group type: EXPERIMENTAL
Intervention: haemoglobin binding to RBC-membranes
Number of subjects: 349
Study 22998182 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (radical prostatectomy)
Number of subjects: 1151
Study 22998182 — intervention group
Group type: COMPARATOR
Intervention: Control arm (radical prostatectomy)
Number of subjects: 1151
Study 20003398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive activity intervention consisting of ten 90-minute sessions delivered twice per week over a period of five weeks.
Number of subjects: 160
Study 20003398 — intervention group
Group type: COMPARATOR
Intervention: Non-specific education (control group).
Number of subjects: 160
Study 17312091 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-QOL total score
Number of subjects: 307
Study 17312091 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-QOL observable scales (e.g., activities)
Number of subjects: 307
Study 17312091 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-QOL subscales (energy, mood, thinking)
Number of subjects: 307
Study 15334426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 50 mg twice daily
Number of subjects: 583
Study 15334426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg twice daily
Number of subjects: 583
Study 15334426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg twice daily
Number of subjects: 583
Study 15334426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily
Number of subjects: 583
Study 15334426 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg twice daily
Number of subjects: 583
Study 15334426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study 11264762 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized commercial formula
Number of subjects: 17
Study 11264762 — intervention group
Group type: COMPARATOR
Intervention: Blenderized formula
Number of subjects: 17
Study 9884846 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume, low-pressure cuff at various airway pressures (10, 15, 20, 25, 30 cm H2O)
Number of subjects: 61
Study 7983513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 0
Study 7983513 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 2735156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program for pain management (12 sessions of about 90 min each)
Number of subjects: 25
Study 2735156 — intervention group
Group type: COMPARATOR
Intervention: Waiting-for-treatment control group
Number of subjects: 25
Study 1101762 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 100 ppm of carbon monoxide
Number of subjects: 10
Study 1101762 — intervention group
Group type: COMPARATOR
Intervention: Compressed, purified air
Number of subjects: 10
Study 30672339 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 0
Study 30672339 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28211216 — intervention group
Group type: EXPERIMENTAL
Intervention: eplerenone 50 mg
Number of subjects: 51
Study 28211216 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study 25839089 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthermal therapeutic ultrasound
Number of subjects: 30
Study 25839089 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 30
Study 24063830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus atorvastatin 10 mg (Period I)
Number of subjects: 1547
Study 24063830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus atorvastatin 20 mg (Period II)
Number of subjects: 1547
Study 24063830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus atorvastatin 10 mg (Period I) or atorvastatin 20 mg (Period II)
Number of subjects: 1547
Study 24063830 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 1547
Study 24063830 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 1547
Study 24063830 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 1547
Study 21442811 — intervention group
Group type: EXPERIMENTAL
Intervention: Early acupuncture combined with exercise therapy; Xingnao Kaiqiao needling method applied at Shuigou (GV 26), Baihui (GV 20), Neiguan (PC 6) after vital signs stabilized.
Number of subjects: 455
Study 21442811 — intervention group
Group type: COMPARATOR
Intervention: Conventional medicine and/or surgery without rehabilitation therapy (control group).
Number of subjects: 455
Study 18851764 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (if-then plans)
Number of subjects: 0
Study 22293088 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting parenteral oxytetracycline
Number of subjects: 92
Study 22293088 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting parenteral enrofloxacin
Number of subjects: 92
Study 22293088 — intervention group
Group type: COMPARATOR
Intervention: Topical application of potassium permanganate solution
Number of subjects: 92
Study 22293088 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral antibacterials (oxytetracycline or enrofloxacin) for chronic footrot
Number of subjects: 92
Study 15945202 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (one label for one color and one shape, another label for the other cues)
Number of subjects: 0
Study 15945202 — intervention group
Group type: COMPARATOR
Intervention: Group S (one label for both colors and another for both shapes)
Number of subjects: 0
Study 14597211 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen + DEP nasal challenge
Number of subjects: 18
Study 14597211 — intervention group
Group type: COMPARATOR
Intervention: Allergen/placebo nasal challenge
Number of subjects: 18
Study 10363918 — intervention group
Group type: EXPERIMENTAL
Intervention: With attention
Number of subjects: 12
Study 10363918 — intervention group
Group type: COMPARATOR
Intervention: Without attention
Number of subjects: 12
Study 8521432 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual application of APF gel with prior dental prophylaxis
Number of subjects: 329
Study 8521432 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual application of APF gel with prior dental prophylaxis
Number of subjects: 329
Study 8521432 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual application of APF gel without prior dental prophylaxis
Number of subjects: 329
Study 8521432 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual application of APF gel without prior dental prophylaxis
Number of subjects: 329
Study 8521432 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior dental prophylaxis
Number of subjects: 329
Study 8521432 — intervention group
Group type: COMPARATOR
Intervention: No prior dental prophylaxis
Number of subjects: 329
Study 2081143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (50 micrograms/kg over 5 minutes)
Number of subjects: 15
Study 2081143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 160860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovral
Number of subjects: 0
Study 160860 — intervention group
Group type: EXPERIMENTAL
Intervention: Norinyl 1/50
Number of subjects: 0
Study 160860 — intervention group
Group type: EXPERIMENTAL
Intervention: Norlestrin
Number of subjects: 0
Study 27702799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg with dexamethasone 40 mg
Number of subjects: 70
Study 27702799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib 5.5 mg with dexamethasone 40 mg
Number of subjects: 70
Study 27702799 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both doses of ixazomib)
Number of subjects: 70
Study 26242119 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal aspiration of hydrosalpinx combined with auricular point sticking (Group A)
Number of subjects: 229
Study 26242119 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal aspiration of hydrosalpinx (Group B)
Number of subjects: 229
Study 26242119 — intervention group
Group type: COMPARATOR
Intervention: No transvaginal aspiration of hydrosalpinx (Group C)
Number of subjects: 229
Study 23801607 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored therapy regimen (amoxicillin, rabeprazole, and clarithromycin or metronidazole based on mutation detection)
Number of subjects: 1232
Study 23801607 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (amoxicillin, rabeprazole, and clarithromycin) in APC control group
Number of subjects: 1232
Study 23801607 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (amoxicillin, rabeprazole, and metronidazole) in APM control group
Number of subjects: 1232
Study 21120255 — intervention group
Group type: EXPERIMENTAL
Intervention: Test antioxidant regimen (facial wash, day lotion, night crème, eye serum)
Number of subjects: 40
Study 21120255 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (control facial wash, control moisturizer)
Number of subjects: 40
Study 18477782 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mammography plus ultrasound
Number of subjects: 2637
Study 18477782 — intervention group
Group type: COMPARATOR
Intervention: Mammography alone
Number of subjects: 2637
Study 18477782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound alone
Number of subjects: 2637
Study 18477782 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 2637
Study 16920894 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 200 mg telbivudine
Number of subjects: 42
Study 16920894 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg telbivudine
Number of subjects: 42
Study 16920894 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 800 mg telbivudine
Number of subjects: 42
Study 16920894 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat doses of 600 mg/d telbivudine
Number of subjects: 42
Study 12637839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychiatric community care (IPCC)
Number of subjects: 520
Study 12637839 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 520
Study 12637839 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline work
Number of subjects: 520
Study 12637839 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-implemented IPCC programs
Number of subjects: 520
Study 10960377 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 16
Study 10960377 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 16
Study 9007148 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy (18 patients)
Number of subjects: 38
Study 9007148 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy (20 patients)
Number of subjects: 38
Study 1510353 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine
Number of subjects: 70
Study 1510353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 6344983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 240
Study 6344983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin + DTIC
Number of subjects: 240
Study 6344983 — intervention group
Group type: EXPERIMENTAL
Intervention: Leiomyosarcomas
Number of subjects: 240
Study 30446002 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol dose > CrCL-based dose (R+)
Number of subjects: 132
Study 27560013 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast acquisition protocol
Number of subjects: 0
Study 27560013 — intervention group
Group type: COMPARATOR
Intervention: Slow acquisition protocol
Number of subjects: 0
Study 24816725 — intervention group
Group type: EXPERIMENTAL
Intervention: MGN1703 60 mg
Number of subjects: 59
Study 24816725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 22288389 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) combined with fractional laser therapy
Number of subjects: 22
Study 22288389 — intervention group
Group type: COMPARATOR
Intervention: Fractional laser therapy alone
Number of subjects: 22
Study 20094802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber with insoluble 84% polyphenols 4 g twice a day (n = 43)
Number of subjects: 88
Study 20094802 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 45)
Number of subjects: 88
Study 17941096 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 70
Study 17941096 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 70
Study 16382297 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 53
Study 16382297 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 53
Study 12937331 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy and technology-based intervention
Number of subjects: 225
Study 12937331 — intervention group
Group type: COMPARATOR
Intervention: Minimal support control condition
Number of subjects: 225
Study 12937331 — intervention group
Group type: COMPARATOR
Intervention: Structural ecosystems therapy
Number of subjects: 225
Study 12937331 — intervention group
Group type: COMPARATOR
Intervention: Structural ecosystems therapy + computer-telephone integrated system
Number of subjects: 225
Study 12131543 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based regimen
Number of subjects: 754
Study 12131543 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 754
Study 10403596 — intervention group
Group type: EXPERIMENTAL
Intervention: Licensed influenza vaccine
Number of subjects: 139
Study 10403596 — intervention group
Group type: COMPARATOR
Intervention: Subpotent influenza vaccine
Number of subjects: 139
Study 7825615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (2.2 mmol/L)
Number of subjects: 42
Study 7825615 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine, norepinephrine, cortisol, growth hormone, glucagon levels measured at each glucose plateau
Number of subjects: 42
Study 7825615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (21.1 mmol/L)
Number of subjects: 42
Study 2245457 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 48
Study 2245457 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 48
Study 7010529 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 40
Study 7010529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30644838 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 168
Study 30644838 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized light microscopy (PLM)
Number of subjects: 168
Study 30644838 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sucrose and S mutans model
Number of subjects: 168
Study 28314604 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-balloon colonoscopy (DBC)
Number of subjects: 44
Study 28314604 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 44
Study 26212372 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia training (∼ 3300 m)
Number of subjects: 14
Study 24103561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis treatment
Number of subjects: 0